Article

In The Literature: NSAID/Statin Influence on PSA in High-Risk Prostate Cancer Patients

The study, published in Cancer Epidemiology, Biomarkers & Prevention, evaluated the influence of NSAIDs and statins on PSA levels in men with a high prostate cancer risk.

Using a population of 699 men, multiple linear regressions were used to investigate the associations between PSA and concomitant medications, and mixed-effects models were used to investigate these associations with PSAV.

After adjusting for selenium use, age, race, body mass index, and pack-years of smoking, aspirin, other NSAIDs, or statins did not demonstrate statistically significant associations with PSA (P = 0.79, 0.68, and 0.79, respectively) or PSAV (P = 0.23, 0.43, and 0.84, respectively). Results were not altered upon stratifying the sample between men who developed prostate cancer during the course of the study and those who did not.

Results from this study indicate that chronic use of aspirin, other NSAIDs, or statins did not affect PSA levels or PSAV in men at high risk for prostate cancer. Larger prospective studies designed to investigate these relationships are needed to confirm this result.

Link to the article: http://bit.ly/1rHlFf9

Source: Cancer Epidemiology, Biomarker & Prevention

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
David Awad, PharmD, BCOP
Coral Omene, MD, PhD, sitting for a vieo interview
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Coral Omene, MD, PhD, sitting for a vieo interview
David Awad, PharmD, BCOP
Screenshot of Coral Omene, MD, PhD
ASCO 2025
Constance Blunt, MD, medical oncologist, Mary Bird Perkins Cancer Center
Cathy Eng, MD, FACP, FASCO
Nini Wu, MD, Navista
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo